Cadence is the asset: quarters that compound are worth more than quarters that spike
Liquidia's steady climb and Harrow's swing show that in this earnings season the scarce commodity is predictability of conversion, not growth in a single quarter.
Two companies, two shapes of growth
Harrow and Liquidia both reported record-setting quarters. The shape of the lines behind them could hardly differ.
Liquidia's YUTREPIA net product sales reached $222.7 million, up 31% from the second quarter. Non-GAAP adjusted EBITDA rose to $140.5 million, the fifth consecutive quarter of increase, and October patient shipments were the highest monthly level since launch. Each data point continues the last.
Harrow's revenue of $99.3 million was a third-quarter record, up 41% sequentially. But adjusted EBITDA went from $(1.2) million in the second quarter to $21.2 million in the third, and GAAP results swung from a $17.3 million net loss to $9.8 million of net income, helped by a $5.0 million litigation settlement gain. The company reaffirmed its revenue guidance of $350 million to $365 million, yet reset full-year adjusted EBITDA guidance to more than $40 million, with fourth-quarter adjusted EBITDA above $33 million. The prior range was $80 million to $100 million.
Both are growth stories. Only one reads as a compounding story.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Written by CompePharma's editorial system (AI-assisted, model claude-sonnet-5-5) strictly from the official material listed. It can contain errors; check the sources. Not investment advice.
Reimbursement, not approval, is the commercial gate, and leaders should plan accordingly
This month's payer decisions from CMS, China's NRDL and Medicare show that price and access are set by policy calendars. Companies that treat them as afterthoughts will pay for it.
Show your working: launch revenue is the lagging indicator, and this season proves it
Headline growth rates from small launches are easy to produce and hard to compare. The results that persuade pair revenue with evidence of demand and a plan the economics can fund.
Gross margin is the number that turns a launch into a business
Revenue growth was easy to find in this earnings season. The companies that pair it with unit economics, as Delcath and Autolus have begun to, are the ones that will set their own terms.